Irinotecan/Cetuximab Followed by XELOX/Cetuximab vs the Reverse Sequence in Metastatic CRC
Status:
Terminated
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
This phase II study will evaluate which is the best way to administer cetuximab after
recurrence in 1st line irinotecan+bevacizumab based treatment and to obtain results of the
efficacy of the oxaliplatin+cetuximab combination as 2nd line treatment.